Fraunhofer Institute for Cell Therapy and Immunology IZIAntibody technologies
- Gnoth K, Piechotta A, Kleinschmidt M, Konrath S, Schenk M, Taudte N, Ramsbeck D, Rieckmann V, Geissler S, Eichentopf R, Barendrecht S, Hartlage-Rübsamen M, Demuth H-U, Roßner S, Cynis H, Rahfeld J-U, Schilling S. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimers Res Ther. 2020 Nov 14;12(1):149. doi: 10.1186/s13195-020-00719-x
- Hettmann T, Gillies SD, Kleinschmidt M, Piechotta A, Makioka K, Lemere CA, Schilling S, Rahfeld J-U, Lues I. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation. Sci Rep. 2020 Feb 24;10(1):3294. doi: 10.1038/s41598-020-60319-5
- Sebastian Monasor L, Müller SA, Colombo AV, Tanrioever G, König J, Roth S, Liesz A, Berghofer A, Piechotta A, Prestel M, Saito T, Saido TC, Herms J, Willem M, Haass C, Lichtenthaler SF, Tahirovic S. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Elife. 2020 Jun 8;9:e54083. doi: 10.7554/eLife.54083
- Hartlage-Rübsamen M, Bluhm A, Piechotta A, Linnert M, Rahfeld J-U, Demuth H-U, Lues I, Kuhn P-H, Lichtenthaler SF, Roßner S, Höfling C. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation. Molecules. 2018 Apr 17;23(4):924. doi: 10.3390/molecules23040924
- Piechotta A, Parthier C, Kleinschmidt M, Gnoth K, Pillot T, Lues I, Demuth H-U, Schilling S, Rahfeld J-U, Stubbs MT. Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy. J Biol Chem. 2017 Jul 28;292(30):12713-12724. doi: 10.1074/jbc.M117.777839. Epub 2017 Jun 16.